Nxera Pharma UK | Heptares Therapeutics

The company's core asset is its proprietary StaR® (Stabilised Receptor) technology, a platform dedicated to overcoming the inherent instability of GPCRs when removed from their cellular environment. This technology engineers the GPCRs to maintain their structure, allowing for detailed 3D analysis through methods like X-ray crystallography. This process facilitates Structure-Based Drug Design (SBDD), enabling the precise creation of small molecule and biologic drug candidates with potentially higher efficacy, improved selectivity, and fewer side effects. The platform is aimed at historically challenging or 'undruggable' GPCR targets implicated in a wide array of human diseases.

Heptares' business model operates on a dual front: developing its own pipeline of drug candidates and forming strategic collaborations with major pharmaceutical companies. Revenue is generated through upfront payments, research funding, milestone payments contingent on development and regulatory successes, and royalties on the net sales of commercialized products from these partnerships. The company has established numerous high-value collaborations with global firms including Pfizer, AstraZeneca, Novartis, and Genentech. This model proved successful, culminating in its acquisition by Japan's Sosei Group in February 2015 for up to $400 million, a deal comprising $180 million in cash and $220 million in potential milestone payments. Post-acquisition, Heptares continues to operate its R&D hub in the UK, driving a diverse pipeline focused on neurology, immunology, gastroenterology, and inflammatory diseases.